● Recruiting

A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Condition: AML · MDS · Sponsor: TScan Therapeutics, Inc.

PhasePhase 1

Planned participants310

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, MMUD, or MUD

This description comes directly from the study's public registry record.

Talk to the study team

Tim White · (857) 399-9500 · medicalaffairs@tscan.com

Always discuss trial participation with your own doctor first.

Locations (21)

City of Hope	Duarte, California, United States	Recruiting
University of Colorado - Anschutz Cancer Center	Aurora, Colorado, United States	Recruiting
SCRI - Colorado Blood Cancer Institute	Denver, Colorado, United States	Recruiting
Yale	New Haven, Connecticut, United States	Recruiting
Memorial Cancer Institute	Hollywood, Florida, United States	Recruiting
Moffitt Cancer Institute	Tampa, Florida, United States	Recruiting
Northside Hospital	Atlanta, Georgia, United States	Recruiting
Johns Hopkins University	Baltimore, Maryland, United States	Recruiting
Mass General Hospital	Boston, Massachusetts, United States	Recruiting
Dana-Farber Cancer Institute - Hematology/Oncology	Boston, Massachusetts, United States	Recruiting
Karmanos Cancer Institute	Detroit, Michigan, United States	Recruiting
Hackensack University Medical Center	Hackensack, New Jersey, United States	Recruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05473910